- Home
- TRNR vs TCRT Comparison
TRNR vs TCRT Comparison
Compare TRNR & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRNR
- TCRT
- Stock Information
- Founded
- TRNR 2017
- TCRT 1998
- Country
- TRNR United States
- TCRT United States
- Employees
- TRNR N/A
- TCRT N/A
- Industry
- TRNR Consumer Electronics/Appliances
- TCRT Biotechnology: Pharmaceutical Preparations
- Sector
- TRNR Technology
- TCRT Health Care
- Exchange
- TRNR Nasdaq
- TCRT Nasdaq
- Market Cap
- TRNR 5.8M
- TCRT 4.8M
- IPO Year
- TRNR 2023
- TCRT N/A
- Fundamental
- Price
- TRNR $3.50
- TCRT $2.51
- Analyst Decision
- TRNR
- TCRT
- Analyst Count
- TRNR 0
- TCRT 0
- Target Price
- TRNR N/A
- TCRT N/A
- AVG Volume (30 Days)
- TRNR 369.8K
- TCRT 338.8K
- Earning Date
- TRNR 11-13-2025
- TCRT 11-13-2025
- Dividend Yield
- TRNR N/A
- TCRT N/A
- EPS Growth
- TRNR N/A
- TCRT N/A
- EPS
- TRNR N/A
- TCRT N/A
- Revenue
- TRNR $6,972,000.00
- TCRT $6,000.00
- Revenue This Year
- TRNR $578.14
- TCRT $5,680,500.00
- Revenue Next Year
- TRNR $130.65
- TCRT N/A
- P/E Ratio
- TRNR N/A
- TCRT N/A
- Revenue Growth
- TRNR 373.32
- TCRT N/A
- 52 Week Low
- TRNR $2.81
- TCRT $1.31
- 52 Week High
- TRNR $330.00
- TCRT $6.20
- Technical
- Relative Strength Index (RSI)
- TRNR 42.94
- TCRT 55.40
- Support Level
- TRNR $3.10
- TCRT $2.20
- Resistance Level
- TRNR $3.81
- TCRT $2.40
- Average True Range (ATR)
- TRNR 0.51
- TCRT 0.19
- MACD
- TRNR 0.07
- TCRT 0.08
- Stochastic Oscillator
- TRNR 45.76
- TCRT 97.96
About TRNR Interactive Strength Inc.
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.